Skip to main content

Table 1 Published datasets included in the meta-analysis

From: A functional Notchsurvivin gene signature in basal breast cancer

Study n Median age (years) Microarray Tumor size Lymph nodes (LN) Treatment Stage/grade
Chin and colleagues [55] 118 55.3 (SD = 14.3) Affymetrix 2.6 cm (SD = 1.3) 67 LN-positive, 51 LN-negative 60% tamoxifen, 52% adjuvant chemotherapy, 51% radiation 26 stage 1, 70 stage 2, 14 stage 3, 5 stage 4; 10 grade 1, 42 grade 2, 61 grade 3; 5 unknown
Desmedt and colleagues [56] 198 47 (all < 61) Affymetrix < 5 cm Node-negative   T1–T2
Ginestier and colleagues [57] 55   Affymetrix    19 amplified for 20q13, 36 unamplified for 20q13 Consecutive cases, unilateral localized invasive breast cancer
Hess and colleagues [58] 133 Training set, 52 (range 29 to 79); validation set, 50 (range 28 to 73) Affymetrix    Preoperative weekly paclitaxel and fluorouracil–doxorubicin–cyclophosphamide chemotherapy Stage I, stage II, stage III
Ivshina and colleagues [59] 249 (Uppsala cohort) 62.3 Affymetrix 2.9 cm 35% node-positive 30.3% endocrine therapy, 10.7% chemotherapy, 1.7% combination therapy, 58.8% no systemic therapy 68 grade 1, 126 grade 2, 55 grade 3
Miller and colleagues [60] 251 62.1 (SD = 13.9) Affymetrix 22.4 mm (SD = 12.5) 84/253 LN metastasis, 160 node-negative, 9 unknown node status 143 no adjuvant therapy; others with systemic adjuvant therapy, and/or chemotherapy  
Minn and colleagues [61] 82 55.8 (SD = 13.5) Affymetrix 3.68 cm (SD = 1.77 cm) Average 3.5 (SD = 5.98) axillary LN Adjuvant chemotherapy and/or hormonal therapy  
Richardson and colleagues [62] 39   Affymetrix     
Saal and colleagues [37] 105 61 (range 26 to 77) Non-Affymetrix 27 mm (range 2 to 50 mm) 65 (62%) LN-positive Treated uniformly with 2 years of adjuvant tamoxifen Stage II, primary breast cancer
Sotiriou and colleagues [63] 119 (KJ125 dataset) 45% < 50, 55% > 50 Affymetrix 61% < 2 cm, 39% > 2 cm LN-negative No adjuvant systemic therapy 34 grade 1, 46 grade 2, 28 grade 3, 17 not available
Turashvili and colleagues [32] 10   Affymetrix     3 grade I, 5 grade II, 2 grade III
van de Vijver and colleagues [64] 295 < 52 Non-Affymetrix < 5 cm 151 LN-negative, 144 LN-positive Modified radical mastectomy or breast-conserving surgery Stage I or stage II breast cancer
Wang and colleagues [65] 286 54 (SD = 12) Affymetrix   LN-negative No adjuvant treatment  
Yu and colleagues [38] 96 (only 68 with Notch-1 and survivin data) 55 (SD = 10.9) Affymetrix 37.7 mm (SD = 17.9) 37.5% LN-negative   2 unknown grade, 5 grade I, 26 grade II, 63 grade III
Zhao and colleagues [36] 59 (35 intraductal carcinoma, 17 intralobular carcinoma; three from each with unknown ER status) Ductal, 53 (SD = 15.5); lobular, 63.5 (SD = 14.0) Non-Affymetrix   Ductal, 16 LN-positive, 16 LN-negative, 3 LN unknown; lobular, 7 LN-positive, 7 LN-negative, 4 LN unknown   Ductal, 5 grade I, 19 grade II, 11 grade III; lobular, 17 grade II, 1 grade I
  1. Sixteen datasets derived from an unbiased search of human breast cancer microarrays on Oncomine were identified that matched the study criteria.